pembrolizumab
merck
['pembro', 'rcc,(-irccs),(-srcc),(-urcc)', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'key,note,564', 'sarcoma', ' uc,(-ucsd),(-ucsf),']
subgroup analysis of keynote-564 by uiss risk group ~75% int risk dfs benefit seen across int (hr:0.65)/high (0.77)/m1ned(0.28) dmfs benefit seen across int (hr:0.65)/high (0.79)/m1ned(0.28) consist benefits across ajcc stage and tnm status/nuclear grade
#gu23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @AUB_Lebanon and @MCG_Urology